432 related articles for article (PubMed ID: 22143140)
1. Practical implications of gene-expression-based assays for breast oncologists.
Prat A; Ellis MJ; Perou CM
Nat Rev Clin Oncol; 2011 Dec; 9(1):48-57. PubMed ID: 22143140
[TBL] [Abstract][Full Text] [Related]
2. Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome.
Barry WT; Kernagis DN; Dressman HK; Griffis RJ; Hunter JD; Olson JA; Marks JR; Ginsburg GS; Marcom PK; Nevins JR; Geradts J; Datto MB
J Clin Oncol; 2010 May; 28(13):2198-206. PubMed ID: 20368555
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.
Wirapati P; Sotiriou C; Kunkel S; Farmer P; Pradervand S; Haibe-Kains B; Desmedt C; Ignatiadis M; Sengstag T; Schütz F; Goldstein DR; Piccart M; Delorenzi M
Breast Cancer Res; 2008; 10(4):R65. PubMed ID: 18662380
[TBL] [Abstract][Full Text] [Related]
4. Biologic markers determine both the risk and the timing of recurrence in breast cancer.
Esserman LJ; Moore DH; Tsing PJ; Chu PW; Yau C; Ozanne E; Chung RE; Tandon VJ; Park JW; Baehner FL; Kreps S; Tutt AN; Gillett CE; Benz CC
Breast Cancer Res Treat; 2011 Sep; 129(2):607-16. PubMed ID: 21597921
[TBL] [Abstract][Full Text] [Related]
5. Hormone receptor and ERBB2 status in gene expression profiles of human breast tumor samples.
Dvorkin-Gheva A; Hassell JA
PLoS One; 2011; 6(10):e26023. PubMed ID: 22022496
[TBL] [Abstract][Full Text] [Related]
6. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay.
Perreard L; Fan C; Quackenbush JF; Mullins M; Gauthier NP; Nelson E; Mone M; Hansen H; Buys SS; Rasmussen K; Orrico AR; Dreher D; Walters R; Parker J; Hu Z; He X; Palazzo JP; Olopade OI; Szabo A; Perou CM; Bernard PS
Breast Cancer Res; 2006; 8(2):R23. PubMed ID: 16626501
[TBL] [Abstract][Full Text] [Related]
7. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer.
Cascione L; Gasparini P; Lovat F; Carasi S; Pulvirenti A; Ferro A; Alder H; He G; Vecchione A; Croce CM; Shapiro CL; Huebner K
PLoS One; 2013; 8(2):e55910. PubMed ID: 23405235
[TBL] [Abstract][Full Text] [Related]
8. Molecular classification of estrogen receptor-positive/luminal breast cancers.
Geyer FC; Rodrigues DN; Weigelt B; Reis-Filho JS
Adv Anat Pathol; 2012 Jan; 19(1):39-53. PubMed ID: 22156833
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive profiling of biological processes reveals two major prognostic subtypes in breast cancer.
Chen F; Gao S; Wang F; Ma J; Zhang M; Lv M; Zhou Q; Fu Z; Lu C; Yin H
Tumour Biol; 2016 Mar; 37(3):3365-70. PubMed ID: 26446459
[TBL] [Abstract][Full Text] [Related]
10. Molecular breast cancer subtypes in premenopausal African-American women, tumor biologic factors and clinical outcome.
Ihemelandu CU; Leffall LD; Dewitty RL; Naab TJ; Mezghebe HM; Makambi KH; Adams-Campbell L; Frederick WA
Ann Surg Oncol; 2007 Oct; 14(10):2994-3003. PubMed ID: 17647064
[TBL] [Abstract][Full Text] [Related]
11. Exploring novel targets of basal-like breast carcinoma by comparative gene profiling and mechanism analysis.
Wu YM; Hu W; Wang Y; Wang N; Gao L; Chen ZZ; Zheng WQ
Breast Cancer Res Treat; 2013 Aug; 141(1):23-32. PubMed ID: 23933801
[TBL] [Abstract][Full Text] [Related]
12. Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review.
Szymiczek A; Lone A; Akbari MR
Clin Genet; 2021 May; 99(5):613-637. PubMed ID: 33340095
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of the intrinsic molecular subtypes of breast cancer.
Prat A; Pineda E; Adamo B; Galván P; Fernández A; Gaba L; Díez M; Viladot M; Arance A; Muñoz M
Breast; 2015 Nov; 24 Suppl 2():S26-35. PubMed ID: 26253814
[TBL] [Abstract][Full Text] [Related]
14. Molecular signatures in breast cancer.
Lal S; McCart Reed AE; de Luca XM; Simpson PT
Methods; 2017 Dec; 131():135-146. PubMed ID: 28669865
[TBL] [Abstract][Full Text] [Related]
15. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.
Sørlie T; Wang Y; Xiao C; Johnsen H; Naume B; Samaha RR; Børresen-Dale AL
BMC Genomics; 2006 May; 7():127. PubMed ID: 16729877
[TBL] [Abstract][Full Text] [Related]
16. Patient profiling in breast cancer--is knowledge power?
Kirk R; Villanueva MT; Hutchinson L
Nat Rev Clin Oncol; 2011 Dec; 9(1):1. PubMed ID: 22186933
[No Abstract] [Full Text] [Related]
17. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.
Yau C; Esserman L; Moore DH; Waldman F; Sninsky J; Benz CC
Breast Cancer Res; 2010; 12(5):R85. PubMed ID: 20946665
[TBL] [Abstract][Full Text] [Related]
18. Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care.
Tebbit CL; Zhai J; Untch BR; Ellis MJ; Dressman HK; Bentley RC; Baker JA; Marcom PK; Nevins JR; Marks JR; Olson JA
Breast Cancer Res Treat; 2009 Dec; 118(3):635-43. PubMed ID: 19224362
[TBL] [Abstract][Full Text] [Related]
19. Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.
Karn T; Pusztai L; Holtrich U; Iwamoto T; Shiang CY; Schmidt M; Müller V; Solbach C; Gaetje R; Hanker L; Ahr A; Liedtke C; Ruckhäberle E; Kaufmann M; Rody A
PLoS One; 2011; 6(12):e28403. PubMed ID: 22220191
[TBL] [Abstract][Full Text] [Related]
20. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.
Guiu S; Michiels S; André F; Cortes J; Denkert C; Di Leo A; Hennessy BT; Sorlie T; Sotiriou C; Turner N; Van de Vijver M; Viale G; Loi S; Reis-Filho JS
Ann Oncol; 2012 Dec; 23(12):2997-3006. PubMed ID: 23166150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
